MétaCan
Menu
← Back to cohort
Record W4237166782 · doi:10.5489/cuaj.146

Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours

2012· article· en· W4237166782 on OpenAlexafffundvenue
Michel S. Beausoleil, D. Scott Ernst, Larry Stitt, Eric Winquist

Bibliographic record

VenueCanadian Urological Association Journal · 2012
Typearticle
Languageen
FieldMedicine
TopicTesticular diseases and treatments
Canadian institutionsWestern UniversityLondon Health Sciences CentreUniversity of Toronto
FundersLondon Health Sciences Centre
KeywordsChemotherapyGerm cellOncologyMedicineSalvage therapyGerm cell tumorsInternal medicineBiologyGeneticsGene

Abstract

fetched live from OpenAlex

Introduction: Some men with metastatic germ cell tumours that have progressed after response to initial cisplatin-based combination chemotherapy are cured with conventional dose first salvage chemotherapy (CDCT) -however, many are not.High-dose chemotherapy with autologous stem cell rescue (HDCT) may be of value in these patients.Prognosis has recently been better defined by International Prognostic Factor Study Group (IPFSG) prognostic factors.HDCT after response to CDCT has been offered at our institution over the past two decades.We retrospectively assessed the validity of the IPFSG prognostic factors in our patients and evaluated the value of HDCT.Methods: We identified eligible men with metastatic germ cell tumour progressed after at least 3 cycles of cisplatin-based chemotherapy and treated with cisplatin-based CDCT alone or with carboplatin-based HDCT.We also collected their clinical data.Patients were classified into risk groups using IPFSG factors, and progression-free and overall survival factors were analyzed and compared in patients treated with CDCT alone and with HDCT.Results: We identified 38 eligible first salvage patients who had received a median of 4 cycles (range, 1 to 7 cycles) of CDCT.Twenty patients received CDCT alone and 18 patients received CDCT plus HDCT.The overall median progression-free survival was 24.6 months (95%CI, 7.3 to 28.7 months) and overall median overall survival was 34.6 months (95%CI, 17.2 to 51.3 months).Distribution by IPFSG category and 2-year progression-free survival and 3-year overall survival rates within each risk category were very similar to the IPFSG results.There were two toxic deaths with CDCT and none with HDCT.Overall, patients treated with CDCT plus HDCT had improved progression-free survival and overall survival.Conclusions: The IPFSG prognostic risk factors appeared valid in our patient population.The safety of HDCT with etoposide and carboplatin was confirmed.HDCT was associated with improved progression-free survival and overall survival outcomes, consistent with observations of the IPFSG group.Ideally, the value of optimal HDCT should be determined in comparison to optimal CDCT as first salvage therapy in men with metastatic germ cell tumour with a randomized trial.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.238
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Urological Association Journal→Same topicTesticular diseases and treatments→French-language works237,207→